Get the Stockscreener App
1.49
2.05%
0.03
Metavia Inc stock is traded at $1.49, with a volume of 69,151.
It is up +2.05% in the last 24 hours and down -22.80% over the past month.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
See More
Previous Close:
$1.46
Open:
$1.47
24h Volume:
69,151
Relative Volume:
0.02
Market Cap:
$7.69M
Revenue:
-
Net Income/Loss:
$-13.13M
P/E Ratio:
-0.2476
EPS:
-6.0188
Net Cash Flow:
$-15.15M
1W Performance:
+0.00%
1M Performance:
-22.80%
6M Performance:
-9.15%
1Y Performance:
-78.84%
1-Day Range:
$1.4636
$1.52
1-Week Range:
$1.42
$1.52
52-Week Range:
$0.9661
$19.03
Metavia Inc Stock (MTVA) Company Profile
Name
Metavia Inc
Sector
Industry
Phone
(857) 702-9600
Address
545 CONCORD AVENUE, CAMBRIDGE
Compare MTVA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTVA
Metavia Inc
|
1.49 | 7.59M | 0 | -13.13M | -15.15M | -6.0188 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Metavia Inc Stock (MTVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Metavia Inc Stock (MTVA) Latest News
MetaVia Inc. (NASDAQ: MTVA) Share Price, MTVA Stock News, MTVA Share Price & Updates - Kalkine
MTVA: Dose Titration Complete in Phase 1 Part 3 Study of DA-1726 - Yahoo Finance
MetaVia (MTVA): Buy Rating Reiterated as DA-1726 Nears Key 4Q26 Data; $20 Price Target Reaffirmed - TipRanks
MetaVia Inc (MTVA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MetaVia’s DA-1726 Reaches Highest Doses in Phase 1 Study Ahead of 2026 Results - The Clinical Trial Vanguard
MetaVia Inc reports results for the quarter ended June 30Earnings Summary - TradingView
MetaVia Advances DA-1726 and Vanoglipel in Q2 Update - TipRanks
MetaVia Inc. Q2 2026: Net loss $5.3M, EPS $(0.90) — 10-Q Summary - TradingView
MTVA: Q2 2026 saw clinical progress and a $5.3M net loss, with cash reserves at $12.6M - TradingView
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
MetaVia's DA-1726 hits top doses in Phase 1; 16-week data expected Q4 2026 with strong obesity and liver results - pluang.com
MetaVia Inc. (MTVA) Holds Steady at $1.46 as Shares Consolidate Between Key LevelsFear Greed Index - dars.gov.et
MetaVia Inc expected to post a loss of 82 cents a shareEarnings Preview - TradingView
MetaVia Inc. (MTVA) Slips to $1.42 as Stock Tests Key Support at $1.35Volume Gap - dars.gov.et
MTVA: Advancing next-gen obesity and MASH therapies with strong clinical data and near-term catalysts - TradingView
Form S-1 MetaVia Inc For: 29 July By Investing.com - Investing.com Nigeria
MTVA|MetaVia Inc|Price:1.450|Chg%:-0.030 - TradingKey
MetaVia Inc (MTVA) Income Statement - TradingKey
MetaVia Inc (MTVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MetaVia Inc (MTVA) Dividends & Stock Splits: Historical Payouts and Event Timeline - tradingkey.com
MetaVia Inc (MTVA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dong-A ST, Metavia push Vanoglipel to lead MASH, diabetes therapiesCHOSUNBIZ - Chosunbiz
MetaVia Inc (MTVA) Institutional Confidence - TradingKey
MetaVia Inc (MTVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MetaVia Inc. (MTVA) Slips 1.99% as Shares Trade Near Key Support LevelsArms Index - dars.gov.et
MetaVia Inc (MTVA) Valuation: PE, PB & Fair Value Analysis - TradingKey
MetaVia Inc (MTVA) Cash Flow - TradingKey
MTVA|MetaVia Inc|Price:1.430|Chg%:-0.060 - tradingkey.com
MetaVia Inc. Revenue Breakdown – NASDAQ:MTVA - TradingView
MetaVia (MTVA) Stock Forum and Discussion - Moomoo
MetaVia completes dose titration in obesity drug trial By Investing.com - Investing.com Nigeria
$MetaVia (MTVA.US)$ - Moomoo
MTVA Stock Jumps As Obesity Drug Trial Hits Key Milestone - StocksToTrade
MetaVia(MTVA) Stock Options Chain | Quotes & News - Moomoo
MetaVia (MTVA) Investor presentation Summary - Quartr
MetaVia (MTVA) Emerging Growth Virtual Conference Summary - Quartr
MetaVia (MTVA) Emerging Growth Conference 93 Summary - Quartr
MetaVia (MTVA) Q4 2025 earnings summary - Quartr
MetaVia (MTVA) Proxy filing Summary - Quartr
Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
H.C. Wainwright reiterates MetaVia stock rating on dose milestone - Investing.com UK
Analyst Maintains Buy on MetaVia, Keeps $8 Price Target as DA-1726 Next-Gen Obesity Data Advances - TipRanks
H.C. Wainwright reiterates MetaVia stock rating on dose milestone By Investing.com - Investing.com Australia
MTVA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
MetaVia Inc. (MTVA) Faces Selling Pressure as Shares Approach Key SupportFloat Adjusted Cap - dars.gov.et
MetaVia reaches highest target doses in Phase 1 obesity trial - scanx.trade
MetaVia Completes Dose Titration in Phase 1 DA-1726 Obesity Trial; Topline Results Expected Q4 2026 - Minichart
MetaVia completes dose titration in obesity drug trial - Investing.com
MetaVia Advances DA-1726 Obesity Trial to Top Doses - TipRanks
MetaVia completes dose titration in Phase 1 Part 3; topline data on track for Q4 2026 - TradingView
MetaVia (NASDAQ: MTVA) completes DA-1726 Phase 1 dose titration milestone - Stock Titan
Metavia Inc Stock (MTVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):